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A gene coding for a N-terminal precursor of interleukin-lfl (IL-lfl) was cloned and expressed in E. coli. The isolated 
Met-Glu-Ala-Glu-IL-lfl precursor was enzymatically converted to IL-lfl by means of dipeptidylaminopeptidase (DAP 
I). This method ensured a correct N-terminal residue and the often observed expression of Met-IL-lfl was thus avoided. 
The pure and physically homogeneous product exhibited the characteristic properties of natural IL-lfl. The in vitro bio- 
logical activity was measured in the lymphocyte-activating factor assay and was compared to that of natural IL-lfl 
isolated from stimulated monocyte culture using exactly the same purification procedure. The specific biological activity 
of both products was 2 × 10 -8 U/rag indicating that the recombinant product exhibits full biological activity. 
Interleukin-lfl; Gene expression; Enzymatic onversion; Dipeptidylaminopeptidase 
1. INTRODUCTION 
Interleukin-1 (IL-1) is a common designation for 
the ce and ~' type of IL-1 molecules with a broad 
range of biological activities related to the acute- 
phase response to microbial infection or injury. 
Recently in vitro studies have demonstrated that 
IL-lfl selectively affects the insulin producing ~'- 
cells of the pancreas, resulting in decreased syn- 
thesis of insulin and finally destruction of the fl- 
cells [1]. Access to large amounts of well 
characterized recombinant IL-lfl is required for 
further elucidation of the above-mentioned cyto- 
toxicity. Here we report a simple and efficient large 
scale procedure for the production of IL-I~' based 
on a method in which an E. coli produced precur- 
sor to IL-lfl is converted to a natural IL- ld in vitro 
using the enzyme dipeptidylaminopeptidase I 
(DAP-I, EC 3.4.14.1). See fig.1 for detailed ex- 
planation of the strategy. To enable a specific 
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determination of the biological activity of the 
recombinant IL-I~', interleukin-l~ was purified 
from activated monocytes using the same purifica- 
tion procedure as described for the bacterial pro- 
tein, thus eliminating the uncertainty present when 
different purification procedures are used. 
2. EXPERIMENTAL 
2.1. Construction of expression vector and conditions for 
expression 
The hGH expression plasmid pHD86SPI3 (SP9b) [2] was cut 
with BamH1/Sall, treated with Klenow DNA polymerase I + 
dNTP and religated, resulting in the plasmid pHD166SP9b. 
This plasmid was cut with PvulI/EcoRI to remove the hGH 
gene. Instead the EcoRI/Hindlll poly linker fragment from 
pUC18 filled in at the HindllI site was introduced, resulting in 
the expression vector pHD162SP9b. The synthetic IL-lfl gene 
was inserted between the ClaI and XmaI sites to obtain the ex- 
pression plasmids pHD228 or pHD230. E. coli MC1061 [3] har- 
bouring the plasmid pHD228 or pHD230 was propagated inTB 
medium containing 50 mg ampicillin/l at 37°C to an A6oo be- 
tween 15 and 20. The cells were harvested by centrifugation. 
2.2. Isolation of MEAE-IL-I~ and its conversion to IL-1B 
MEAE-IL-I~ was extracted from bacterial suspension as 
described by Kronheim [4] except that the buffer used was 
0.2 M Na-citrate, pH 3.5. The extract was filtered on 0.8/zm 
Millex filter, dialyzed against 20 mM Na-citrate, 0.5 mM 
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Fig.1. Conversion of MEAE-1L-I~ to 1L-I~. The Ala-Pro se- 
quence will not be cleaved as DAP-I does not recognize Pro as 
the second amino acid. 
EDTA, pH 4.0, and applied to a FF-S-Sepharose HR 16/10 
column. 
The pooled MEAE-IL-lfl fraction was converted toIL-1B by 
adding 0.38 U of DAP-I (Cathepsin C, Boehringer Mannheim 
GmbH) per mg protein directly to the FF-S pooled fractions. 
After 45 min at 37°C, the reaction mixture was dialyzed over- 
night against 10 mM Na-citrate, 1mM EDTA, pH 4.0, at 4°C. 
The dialysate was adjusted to pH 9.5 and applied to a FF-Q- 
Sepharose HR 10/10 column. The recombinant IL-IB fraction 
was concentrated by ultrafiltration using a 10 ml Nova cell 
(8 kDa cut off) to a volume of 2.0 ml and applied to a G-75 
Sephadex K16 (1.6 × 90 cm) column. The product was stored in 
50 mM Tris-C1, pH 8.0, at -20°C. Monocyte IL-1B from ac- 
tivated human monocytes [5] was purified using exactly the 
same methods as for recombinant IL-1B, except that the DAP-! 
conversion was omitted. 
2.3. Analytical methods 
The IL-I~ was subjected to amino acid analysis (LKB 451 
Alpha Plus) after 24 h hydrolysis at 110°C in constant boiling 
HCI. Free cysteine was determined asthe pyridyl-ethyl cysteine 
derivative. The protein was sequenced by automated Edman 
degradation (Applied Biosystems 477A). The molecular mass 
was determined by the plasma desorption/time of flight tech- 
nique [6]. Electrophoresis was carried out using 8-25 gradient 
Phastgels and IEF 3-9 Phastgels (Pharmacia-LKB iotech- 
nology). Reverse-phase chromatography was performed on a 
Brownlee column (Applied Biosystem 130A) (RP300, C8 
(2.1 × 30 mm)). E~.7~7~0 = .59 was used for protein determina- 
tion. The amount of monocyte-derived IL-1~' was determined by
means of an internal ELISA assay calibrated against the WHO 
international reference 1L-IB standard. The biological activity 
and test for endotoxins were performed as described in [5] and 
[71. 
3. RESULTS AND DISCUSSION 
3.1. Design and construction of  the IL-1B gene 
The synthetic gene was designed on the basis of 
the published amino acid sequence of the protein 
[8] using the codons most frequently found in 
highly expressed E. coil genes [9]. To allow for fur- 
ther manipulat ion,  convenient cloning of the 
coding region and insertion of the gene in a suitable 
expression vector, unique restriction cleavage sites 
were introduced into the coding region as well as at 
the 5'- and 3'-ends. The gene was N-terminal ex- 
tended with a sequence ncoding the amino acids 
Met-Glu-Ala-Glu (MEAE) and followed by two 
tandemly arranged stop codons (TAG, TAA)  at the 
C-terminus. 
The synthetic promoter and Shine and Dalgarno 
sequence [10] was chosen as it has been shown to 
direct highly efficient synthesis of B-hGH in E. coli 
in excess of 10/~g/ml (A6oo = 1) [2]. However, the 
total extract from cells harbour ing the initial ex- 
pression plasmid pHD228 was found in a IL-IB- 
specific EL ISA only to contain immunoreactive 
material corresponding to approx. 250 ng 
IL - l f l /ml  (A6o0 = 1). 
Recent studies have highlighted the key role of 
preventing secondary structure formation on the 
mRNA,  particularly in the region comprising the 
Shine and Dalgarno sequence and the translation 
init iat ion codon [11,12]. During the DNA sequenc- 
ing of the synthetic IL- l f l  gene strong secondary 
structure was found to be formed at the beginning 
of the gene (amino acid 4-7, GAG GCG CCG 
GTT).  If this secondary structure is formed in vivo 
it may inhibit the translat ion efficiency. Alteration 
of the sequence by in vitro mutagenesis to be 
similar to the corresponding sequence from the 
published IL-1B cDNA [8] (GAA GCA CCT GTA) 
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Fig.2. Schematic drawing of the expression plasmid. The plas- 
mid consists of a synthetic promoter Shine-Dalgarno sequence 
[10], the synthetic MEAE IL-1B gene, part of the poly linker 
from pUC19, the fd transcription terminator, and the vector 
pATI53 (z~SalI/AEcoRI). 
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resulted in a plasmid (pHD230) which very effi- 
ciently expressed IL-I~ to a level of approx. 
10/zg/ml (A6o0 = 1) (fig.2). 
3.2. Extraction and purification 
The purification profiles of the three chromato- 
graphic separations are shown in fig.3. The frac- 
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Fig.3. Purification of r-IL-lfl and m-lL-lfl. (Upper panel) FF-S-Sepharose chromatography in 30 mM Na-citrate, pH 4.0, 0-1 M NaC1 
gradient at 1.3 ml/cm ~ per min, 4°C of r-IL-l~ (a) and m-IL- 1# (d). (Middle panel) FF-Q-Sepharose chromatography in 50 mM Tris-Cl, 
pH 9.5, 0-0.4 M NaC1 gradient at 1.3 ml/cm ~ per min, 4°C of r- lL- l# (b) and m-lL-l~' (e). (Lower panel) G-75 gel filtration in 0.5 M 
Na-acetate, pH 3.5, of r-IL-l~' on a 1.6 x 90 cm column at 0.1 ml/min, 4°C (c). m-IL-l~' was purified on a 0.9 × 60 cm column at 
0.1 ml/min, 4°C (f). The peak observed at 280 nm comprises high-molecular-mass proteins. No absorbance is observed in the im- 
munoreactive fractions due to the very low protein concentration (ng/ml). (I I) Fractions pooled; ( - - - )  gradient profile. 
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tions pooled in each of the six panels are indicated. 
Two different columns were used for gel filtration, 
thus retention times cannot be compared. The peak 
observed in the purification of m-IL-lfl is a high- 
molecular-mass fraction which eluted before 
IL-lg. The recombinant process was followed by 
SDS electrophoresis (fig.4). Due to the acidic ex- 
traction procedure used only a few other proteins 
are co-extracted. The 14 kDa band present is 
lysozyme added during extraction (lanes 2 and 3). 
A slightly higher mobility of the product is ob- 
served in lanes 4 and 5 due to the decrease of 
molecular mass after DAP-I conversion. The 
purified IL-1/3 is shown in lane 6. 
3.3 .  Characterization 
Total amino acid analysis (table 1) and positive 
identification of the first 42 amino acids by se- 
quence analysis confirmed the primary sequence of 
the IL-l~3. Sequence analysis of 2600 pmol IL-lfl 
(from absorption measurement) indicated Ala as 
the only N-terminal amino acid (with an initial 
yield of 80°70) in accordance with the primary struc- 
ture and gene sequence proving that the enzymatic 
cleavage with DAP-I resulted in removal of the 
MEAE sequence. The PTH detection limit is 
5 pmol for the stable derivatives and 10 pmol for 
the rest. A result of 1.6 mol sulphydryl per tool 
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Fig.4. SDS electrophoresis. Samples for SDS electrophoresis 
were diluted in 0.1 M Tris-Cl, 1 mM EDTA, 2.5% SDS, 0.1 M 
DTT, 0.01% bromophenol blue, pH 8.0. 1/zl was applied. 
Lanes: 1, low molecular mass markers; 2, total cell extract from 
E. coli MC1061/pHD230; 3, extract; 4, FF-S pool; 5, FF-Q 
pool; 6, G-75 pool. 
Table 1 
Amino acid composition 
Amino acid Found Composition Theoretical 
(nmol) (mol/mol) (mol/mol) 
Asx 3.97 17 17 
Thr 1.32 5.6 6 
Ser 2.71 ! 1.6 14 
Glx 5.59 23.9 23 
Pro 2.34 10.0 8 
Gly 1.98 8.5 8 
Ala 1.21 5.2 5 
PE-Cys 1.6 2 
Val 2.59 11.1 11 
Met 1.40 6.0 6 
lie 1.17 5.0 5 
Leu 3.55 15.2 15 
Tyr 0.92 3.9 4 
Phe 2.07 8.9 9 
His 0.25 1.1 1 
Lys 3.54 15.2 15 
Arg 0.80 3.4 3 
Trp n.d. 1 
Total 153 
Samples were subjected to amino acid analysis after 24 h hydro- 
lysis at 110°C in constant boiling HCI. The mol/mol composi- 
tion was calculated relative to Asx 
IL-1B indicates that the two cysteine groups do not 
form a disulphide bond. The theoretical molecular 
mass of IL-I/3 from the amino acid sequence con- 
sidering the content of 13-C and 15-N was 
calculated to be 17 359 a.m.u. The molecular mass 
determined experimentally by PDMS was 
17 360.1 a.m.u. The composition and purity of the 
recombinant material was evaluated by means of 
reverse-phase chromatography on a RP300 C8 col- 
umn and electrophoresis (fig.5). The mean specific 
biological activity was calculated to 3.24 × 108 
U/mg with a standard deviation of 0.6 using the 
WHO reference standard as reference. Results 
were based on IL-1B from three different batches. 
This is in agreement with the specific biological ac- 
tivity calculated for the purified natural monocyte- 
derived IL-I~ of 2.0 x 108 U/mg and with the 
reported specific biological activities of recombi- 
nant IL-lfl, 4.6 × 108 U/mg [13], 1.95 x 108 U/mg 
[4] and of natural IL-I~, 3.2 x 108 [14]. The level 
of endotoxins was found to be 13 pg//zg IL-I~, an 
amount which does not interfere with the 
biological assay. 
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Fig.5. Characterization f recombinant IL-I~'. (a) RP-HPLC on 
RP300, C8 column. A buffer, 0.1% trifluoroacetic acid; B buf- 
fer, 0.085% trifluoroacetic acid, 80% CH3CN. Flow, 
0.1 ml/min; temp., 26°C. (b) Native PAGE. Samples were 
diluted in 0.1 M Tris-C1, 1 mM EDTA, 0.01% bromophenol 
blue, pH 8.0.1/LI was applied. (c) Isoelectric focusing. Samples 
were diluted in 7 M urea. 1/A was applied. 
In conclusion the procedure described results in 
a highly purified IL-1B bulk material possessing the 
correct N-terminal amino acid, alanine. The pro- 
cess is feasible for large scale production of IL-I~' 
thus avoiding the tedious eparation of Met-IL-l~, 
IL-I~ and desAla-IL-l~ described earlier [13,15]. 
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